Hormone-based strategies for management of BrCa1 and 2 carriers

Women found to have mutations of the BrCa 1 or 2 genes face many therapeutic decisions with respect to prevention of ovarian and breast cancer and management of menopausal symptoms after natural or surgical menopause. The first issue is whether these women should undergo breast cancer prevention with an antiestrogen. This issue predominantly affects pre-menopausal women. The majority of data suggest that tamoxifen reduces the risk of breast cancer by approximately 50% of women with these two mutations (RR 0.38 –0.50 for BrCa1 and 0.42–0.63 for BrCa2).
Source: Maturitas - Category: Primary Care Authors: Tags: INV31 Source Type: research